Actively Recruiting
68Ga-NYM096 PET/CT: Tracer Uptake in Various Kinds of Cancer
Led by Peking Union Medical College Hospital · Updated on 2025-09-05
120
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the uptake characteristics of 68Ga-NYM096 PET/CT imaging in various types of tumors, including both primary and metastatic cancer lesions. This prospective, single-center study aims to provide important insights into how different tumors take up this imaging tracer, helping to identify the most promising uses of 68Ga-NYM096 PET/CT for future cancer diagnosis and treatment assessment. Participants will receive a single intravenous dose of 68Ga-NYM096, with the amount adjusted based on body weight. After injection, a whole-body PET/CT scan will be performed approximately 45 to 75 minutes later to capture detailed images of tumor uptake. The study focuses on quantitative analysis of tracer uptake in cancer lesions, measuring factors such as lesion number, maximum standardized uptake value (SUVmax), and tumor-to-background ratio. During the study, participants will undergo the PET/CT imaging procedure and provide informed consent. Researchers will analyze the images to assess tracer uptake characteristics in confirmed tumors. Safety and compliance with study procedures will be monitored. The main outcome is the quantitative assessment of tumor lesions on the 68Ga-NYM096 PET/CT scan, evaluated from study completion to one month after. The study plans to enroll 120 patients with confirmed cancer diagnoses and will follow ethical guidelines throughout the research.
CONDITIONS
Brief Title
68Ga-NYM096 PET/CT in Various Kinds of Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histopathologically confirmed primary or metastatic cancer
- Expected survival of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Provided written informed consent to participate
- Willing and able to follow study procedures as judged by the investigator
You will not qualify if you...
- Received VEGF tyrosine kinase inhibitor treatment within 1 week before 68Ga-NYM096 PET/CT
- Medical conditions that make study procedures unsafe or unsuitable
- Pregnancy or breastfeeding
- Severe claustrophobia preventing PET/CT imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive a single intravenous dose of 68Ga-NYM096 followed by a dedicated whole-body PET/CT scan to evaluate tracer uptake in tumors.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital, Beijing, Beijing 100730
Beijing, China, 100730
Actively Recruiting
Research Team
L
Li Huo, MD
W
Wenjia Zhu, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here